A report published in the Archives of Neurology has found that people with a polymorphism in the CYP46 gene are at increased risk for late-onset Alzheimer?s disease (AD). According to researchers, this gene encodes cholesterol 24-hydroxylase, and previous studies have shown that reducing cholesterol levels in the brain inhibits the generation of beta-amyloid peptides found in AD plaques.The study compared 201 patients with AD with 248 control individuals to assess the CYP46 genotype and the frequency of a particular polymorphism. Researchers found the CYP46*TT genotype to be significantly more common among the patients with AD. The study authors concluded that ?these data are consistent with the possibility that CYP46 is a novel susceptibility gene for Alzheimer?s disease.?
In an accompanying editorial, Dr. Benjamin Wolozin from Loyola University remarked that the possibility of late-onset AD may be an end point for abnormalities that increase the amount of cholesterol in the central nervous system and that ?inhibiting cholesterol metabolism in the brain might represent a viable treatment.?
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs